Pharmacological profile and effects of mitotane in adrenocortical carcinoma

Mitotane is the only adrenolytic drug approved by the Food and Drug Administration for treating adrenocortical carcinoma (ACC). This drug has cytotoxic effects on tumour tissues; it induces cell death and antisecretory effects on adrenal cells by inhibiting the synthesis of adrenocortical steroids,...

Full description

Saved in:
Bibliographic Details
Published in:British journal of clinical pharmacology 2021-07, Vol.87 (7), p.2698-2710
Main Authors: Corso, Claudia Rita, Acco, Alexandra, Bach, Camila, Bonatto, Sandro José Ribeiro, Figueiredo, Bonald Cavalcante, Souza, Lauro Mera
Format: Article
Language:English
Subjects:
adrenocortical carcinoma
mechanism of action
mitotane
pharmacokinetics
therapeutic effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Mitotane is the only adrenolytic drug approved by the Food and Drug Administration for treating adrenocortical carcinoma (ACC). This drug has cytotoxic effects on tumour tissues; it induces cell death and antisecretory effects on adrenal cells by inhibiting the synthesis of adrenocortical steroids, which are involved in the pathogenesis of ACC. However, high doses of mitotane are usually necessary to reach the therapeutic plasma concentration, which may result in several adverse effects. This suggests that important pharmacological processes, such as first pass metabolism, tissue accumulation and extensive time for drug elimination, are associated with mitotane administration. Few studies have reported the pharmacological aspects and therapeutic effects of mitotane. Therefore, the aim of this review was to summarize the chemistry, pharmacokinetics and pharmacodynamics, and therapeutic and toxic effects of mitotane. This review also discusses new perspectives of mitotane formulation that are currently under investigation. Understanding the pharmacological profile of mitotane can improve the monitoring and efficacy of this drug in ACC treatment and can provide useful information for the development of new drugs with specific action against ACC with fewer adverse effects.
ISSN:0306-5251
1365-2125
DOI:10.1111/bcp.14721